All In Biotech

Drug Trial Radar · NCT04541082

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

35

Actual

Start

Oct 26, 2020

Primary completion

Mar 31, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
Sponsor type
Industry
Collaborators
National Institutes of Health (NIH)
First posted
Sep 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting toxicities (DLTs) following single weekly or multiple-day weekly dose regimens of single-agent, oral ONC206 in patients with recurrent, primary central nervous system (CNS) neoplasms.

Conditions

  • Central Nervous System Neoplasms
  • Glioblastoma
  • Gliosarcoma, Adult
  • Anaplastic Oligodendroglioma
  • Anaplastic Astrocytoma
  • Pilocytic Astrocytoma
  • Oligodendroglioma
  • Gliomatosis Cerebri
  • Pleomorphic Xanthoastrocytoma
  • Anaplastic Pleomorphic Xanthoastrocytoma
  • Diffuse Midline Glioma, H3 K27M-Mutant
  • Ependymoma
  • Ependymoma, Anaplastic
  • Medulloblastoma
  • Teratoid Rhabdoid Tumor
  • Neuroectodermal Tumors, Primitive
  • Neuroectodermal Tumors
  • Anaplastic Meningioma
  • Atypical Meningioma
  • Choroid Plexus Neoplasms
  • Pineal Tumor
  • Diffuse Astrocytoma
  • Glial Tumor

Interventions

  • ONC206Drug

    ONC206 is a member of the imipridone class of anti-cancer small molecules that share a unique tri-heterocyclic core chemical structure and target G protein-coupled receptors.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD) of single-agent, oral ONC206Time frame: 28 Days
  2. Number of Participants who Experienced Dose-Limiting Toxicities (DLTs)Time frame: 28 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institutes of Health

    Bethesda, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.